High potency focus Leverage Eirgen’s specialized high containment and high potency OSO/OSD manufacturing capabilities to target pharma and biotech clients with complex, potent molecules seeking compliant, scalable production and global regulatory support.

Capacity expansion Capitalise on the 2025 facility expansion to offer scalable manufacturing capacity (over 500 million units annually) to sponsors looking to de-risk supply chains, with phased capacity planning and fast-track qualification for new programs.

Full lifecycle partner Position Eirgen as a end-to-end partner from early-stage formulation and clinical trial supply to commercial manufacturing and packaging, appealing to companies seeking a single CDMO/CMO for continuity and faster time-to-market.

Geographic expansion Highlight HPRA-approved Waterford facility and European footprint to attract regional biologics and small-molecule clients needing EU GMP compliance, regulatory clarity, and regional supply security.

Industry engagement Utilise active participation in industry events like EuroPLX and AHNTI to generate deal flow and partnerships, targeting license deals, co-development, and strategic manufacturing collaborations with specialty pharma and global innovators.